Journey Medical Corporation (DERM)
USD 6.21
(2.99%)
USD 6.21
(2.99%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.07 Million USD | 103.89% |
| 2022 | -27.51 Million USD | -8.59% |
| 2021 | -25.34 Million USD | -422.77% |
| 2020 | 7.85 Million USD | 49.29% |
| 2019 | 5.25 Million USD | 102.46% |
| 2018 | -213.98 Million USD | 28.75% |
| 2017 | -300.32 Million USD | -231.4% |
| 2016 | -90.62 Million USD | -13.61% |
| 2015 | -79.77 Million USD | -151.66% |
| 2014 | -31.69 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.92 Million USD | 70.99% |
| 2024 Q1 | -10.09 Million USD | -379.56% |
| 2023 FY | 1.07 Million USD | 103.89% |
| 2023 Q3 | 17.24 Million USD | 325.34% |
| 2023 Q4 | -2.1 Million USD | -112.2% |
| 2023 Q1 | -9.56 Million USD | 4.34% |
| 2023 Q2 | -7.65 Million USD | 19.96% |
| 2022 Q2 | -7.14 Million USD | -684.84% |
| 2022 FY | -27.51 Million USD | -8.59% |
| 2022 Q1 | -910 Thousand USD | 90.24% |
| 2022 Q4 | -9.99 Million USD | -5.3% |
| 2022 Q3 | -9.49 Million USD | -32.9% |
| 2021 Q2 | -13.76 Million USD | -2452.65% |
| 2021 Q3 | -12.64 Million USD | 8.12% |
| 2021 Q4 | -9.32 Million USD | 26.3% |
| 2021 FY | -25.34 Million USD | -422.77% |
| 2021 Q1 | 585 Thousand USD | -83.87% |
| 2020 Q3 | 239 Thousand USD | -84.47% |
| 2020 FY | 7.85 Million USD | 49.29% |
| 2020 Q2 | 1.53 Million USD | -22.78% |
| 2020 Q4 | 3.62 Million USD | 1417.15% |
| 2020 Q1 | 1.99 Million USD | 0.0% |
| 2019 Q1 | -62.72 Million USD | 11.03% |
| 2019 FY | 5.25 Million USD | 102.46% |
| 2019 Q3 | -55.17 Million USD | -238.43% |
| 2019 Q2 | -16.3 Million USD | 74.01% |
| 2018 Q2 | -21.23 Million USD | 62.7% |
| 2018 Q3 | -65.32 Million USD | -207.61% |
| 2018 Q4 | -70.49 Million USD | -7.92% |
| 2018 FY | -213.98 Million USD | 28.75% |
| 2018 Q1 | -56.92 Million USD | -6.06% |
| 2017 Q1 | -30.12 Million USD | -281.89% |
| 2017 FY | -300.32 Million USD | -231.4% |
| 2017 Q4 | -53.67 Million USD | 69.85% |
| 2017 Q3 | -178.03 Million USD | -362.43% |
| 2017 Q2 | -38.49 Million USD | -27.82% |
| 2016 Q4 | -7.88 Million USD | 69.6% |
| 2016 Q3 | -25.94 Million USD | 54.33% |
| 2016 FY | -90.62 Million USD | -13.61% |
| 2016 Q2 | -56.79 Million USD | -97.52% |
| 2016 Q1 | -28.75 Million USD | 63.9% |
| 2015 Q1 | -14.23 Million USD | -157.13% |
| 2015 Q2 | -31.57 Million USD | -121.84% |
| 2015 Q3 | -16.27 Million USD | 48.46% |
| 2015 FY | -79.77 Million USD | -151.66% |
| 2015 Q4 | -79.64 Million USD | -389.41% |
| 2014 Q4 | 24.91 Million USD | 0.0% |
| 2014 FY | -31.69 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 166.96 Million USD | 101.242% |
| Embecta Corp. | 221.5 Million USD | 100.936% |
| ANI Pharmaceuticals, Inc. | 46.97 Million USD | 104.413% |
| Dynavax Technologies Corporation | -37.02 Million USD | 94.402% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 98.667% |
| Pacira BioSciences, Inc. | 87.67 Million USD | 102.364% |
| PainReform Ltd. | -9.58 Million USD | 78.37% |
| Aquestive Therapeutics, Inc. | -15.1 Million USD | 86.273% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 56.68% |
| SCYNEXIS, Inc. | 72.66 Million USD | 102.853% |
| China SXT Pharmaceuticals, Inc. | -2.51 Million USD | 17.582% |
| Cosmos Health Inc. | -21.83 Million USD | 90.504% |
| Sunshine Biopharma, Inc. | -4.78 Million USD | 56.68% |
| Safety Shot Inc | -12.18 Million USD | 82.986% |
| Alpha Teknova, Inc. | -35.56 Million USD | 94.171% |
| Intra-Cellular Therapies, Inc. | -159.38 Million USD | 98.699% |
| Bright Green Corporation | -8.89 Million USD | 76.685% |
| Procaps Group, S.A. | 38.97 Million USD | 105.319% |
| Theratechnologies Inc. | -10.62 Million USD | 80.493% |
| Harrow Health, Inc. | 580 Thousand USD | 457.414% |
| Sonoma Pharmaceuticals, Inc. | -4.7 Million USD | 55.903% |
| Biofrontera Inc. | -22.67 Million USD | 90.859% |
| DURECT Corporation | -36.88 Million USD | 94.38% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | 60.657% |
| Cronos Group Inc. | -81.37 Million USD | 97.453% |
| OptiNose, Inc. | -22.74 Million USD | 90.887% |
| Ironwood Pharmaceuticals, Inc. | 209.03 Million USD | 100.992% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | 94.705% |
| RedHill Biopharma Ltd. | 12.63 Million USD | 116.411% |
| Organogenesis Holdings Inc. | 12.52 Million USD | 116.551% |
| Guardion Health Sciences, Inc. | -4.33 Million USD | 52.194% |
| Cumberland Pharmaceuticals Inc. | -6.21 Million USD | 66.623% |
| Radius Health, Inc. | -3.92 Million USD | 47.185% |
| Universe Pharmaceuticals INC | -3.52 Million USD | 41.221% |
| ProPhase Labs, Inc. | -21.61 Million USD | 90.409% |
| Phibro Animal Health Corporation | 53.31 Million USD | 103.888% |
| Procaps Group S.A. | 52.32 Million USD | 103.962% |
| Alvotech | -354.86 Million USD | 99.416% |
| TherapeuticsMD, Inc. | -8.52 Million USD | 75.678% |
| Viatris Inc. | 766.2 Million USD | 100.271% |
| Rockwell Medical, Inc. | -6.67 Million USD | 68.921% |
| Aytu BioPharma, Inc. | -5.25 Million USD | 60.544% |
| SIGA Technologies, Inc. | 83.62 Million USD | 102.479% |
| Tilray Brands, Inc. | -174.74 Million USD | 98.814% |
| Lifecore Biomedical, Inc. | 9.33 Million USD | 122.216% |
| Shineco, Inc. | -17.06 Million USD | 87.853% |
| PetIQ, Inc. | 60.01 Million USD | 103.454% |
| Regencell Bioscience Holdings Limited | -4.73 Million USD | 56.236% |
| Incannex Healthcare Limited | -30.04 Million USD | 93.099% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 100.826% |
| Alimera Sciences, Inc. | -1.47 Million USD | -40.925% |
| Silver Spike Investment Corp. | 7.34 Million USD | 128.242% |
| Assertio Holdings, Inc. | -243.53 Million USD | 99.149% |
| Shuttle Pharmaceuticals Holdings, Inc. | -5.89 Million USD | 64.819% |
| Petros Pharmaceuticals, Inc. | -13.61 Million USD | 84.777% |
| Clever Leaves Holdings Inc. | -15.59 Million USD | 86.706% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 89.661% |
| Avadel Pharmaceuticals plc | -137.84 Million USD | 98.496% |
| Hempacco Co., Inc. | -8.81 Million USD | 76.476% |
| Talphera, Inc. | -16.88 Million USD | 87.726% |
| Alvotech | -354.86 Million USD | 99.416% |
| Eagle Pharmaceuticals, Inc. | 53.45 Million USD | 103.878% |
| Lantheus Holdings, Inc. | 364.64 Million USD | 100.569% |
| Currenc Group, Inc. | -6.64 Million USD | 68.807% |
| Kamada Ltd. | 10.06 Million USD | 120.598% |
| Indivior PLC | -4 Million USD | 48.175% |
| Evoke Pharma, Inc. | -7.43 Million USD | 72.103% |
| Flora Growth Corp. | -50.35 Million USD | 95.883% |
| Cyclo Therapeutics, Inc. | -20.05 Million USD | 89.661% |
| Evolus, Inc. | -49.23 Million USD | 95.789% |
| HUTCHMED (China) Limited | 18.37 Million USD | 111.282% |
| Amphastar Pharmaceuticals, Inc. | 196.98 Million USD | 101.052% |
| Akanda Corp. | -10.05 Million USD | 79.376% |